Worldwide GERD Therapeutics Industry to 2026 – Featuring Phathom Pharmaceuticals, Eisai and Takeda Pharmaceutical Among Others – ResearchAndMarkets.com

Worldwide GERD Therapeutics Industry to 2026 – Featuring Phathom Pharmaceuticals, Eisai and Takeda Pharmaceutical Among Others – ResearchAndMarkets.com




Worldwide GERD Therapeutics Industry to 2026 – Featuring Phathom Pharmaceuticals, Eisai and Takeda Pharmaceutical Among Others – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global Gastroesophageal Reflux Disease (GERD) Therapeutics Market – Analysis By Drug Type, Distribution Channel, By Region, and By Country (2021 Edition): Market Insights and Forecast with Impact of COVID-19 (2021-2026)” report has been added to ResearchAndMarkets.com’s offering.

Global Gastroesophageal Reflux Disease (GERD) Therapeutics Market was valued at USD 5.5 billion in the year 2020.

Companies Mentioned

  • Phathom Pharmaceuticals
  • Eisai
  • Takeda Pharmaceutical Company
  • Daewoong Pharmaceutical
  • Ironwood Pharmaceuticals
  • Johnson & Johnson
  • EndoGastric Solutions
  • CHEPLAPHARM Arzneimittel
  • Merck & Co.
  • Olympus Corporation

The key factors driving growth in the global Gastroesophageal Reflux Disease Therapeutics market is increased public awareness of the disease and its symptoms. The growing incidence of heartburn is likely to create new economic prospects for acid-reducing medications and proton pump inhibitors, resulting in the rapid growth of GERD therapeutics market. Other potential includes an increase in risk of GERD disease in emerging nations and technological advancements that allow for speedier diagnosis of the condition.

Protein pump inhibitors (PPIs) are the front line therapy for the treatment of GERD. The market of GERD is very large in the US and in European countries and mostly catered by PPIs. Although PPIs control the major share of the market, but with PPIs providing limited relief and the treatment generally relapsing within 6-months, the market for acid blockers like Vonoprazan looks very lucrative with physicians also supports its efficacy in GERD management. Also, the US GERD market is highly price sensitive because of the availability of generics in the market and hence any drug, even with higher efficiency, will have to price rationally to gain share of the market.

The increasing prevalence of gastroesophageal reflux disease is correlated with the increasing prevalence of obesity in many countries and presence of other poor diet and lifestyle factors. Several environmental factors and the prominent lifestyle evolution to sedentary habits such as a high dietary fat intake, shorter dinner-to-bed time, and frequent smoking and alcohol consumption have been proven as the high risk factors associated with the prevalence of gastroesophageal reflux diseases.

North America region dominates the Gastroesophageal Reflux Disease Therapeutics Market. High incidence of obesity-driven GERD and innovation in drugs in GERD treatments are factors that have helped cement the potential of the North America GERD therapeutics market. Moreover, high per capita expenditure on healthcare coupled with extended life expectancy of consumers in the region has been creating a sustainable demand for the superior treatment for the GERD in North America.

Scope of the Report

  • The report presents the analysis of Gastroesophageal Reflux Disease Therapeutics Market for the historical period of 2016-2020 and the forecast period of 2021-2026.
  • The report analyses the Gastroesophageal Reflux Disease Therapeutics Market by Drug Type (Antacids, H2 Receptor Blockers and Proton Pump Inhibitors) and Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies).
  • The major regional markets (North America, Europe, Asia Pacific) have been analysed, along with country coverage of North America, Europe and Asia Pacific) and By Country (United States, Canada, Germany, France, United Kingdom, Spain, Italy, China, Japan and India.
  • The market dynamics such as growth drivers, market trends and challenges are analysed in-depth.

Key Topics Covered:

1. Research Methodology and Executive Summary

1. Report scope & Methodology

2. Strategic Recommendations

3. Global Gastroesophageal Reflux Disease Therapeutics Market Product Overview

4. Global Gastroesophageal Reflux Disease Therapeutics Market: An Analysis

4.1 Market Size, By Value, Year 2016-2026

4.2 COVID-19 Impact on Gastroesophageal Reflux Disease Therapeutics Market

5. Global Gastroesophageal Reflux Disease Therapeutics Market Segmentation By Drug Type (By Value)

5.1 Competitive Scenario of Global Gastroesophageal Reflux Disease Therapeutics Market: By Drug Type

5.2 Antacids- Market Size and Forecast (2016-2026)

5.3 H2 Receptor Blockers- Market Size and Forecast (2016-2026)

5.4 Proton Pump Inhibitors- Market Size and Forecast (2016-2026)

6. Global Gastroesophageal Reflux Disease Therapeutics Market Segmentation By Distribution Channel (By Value)

6.1 Competitive Scenario of Global Gastroesophageal Reflux Disease Therapeutics Market: By Distribution Channel

6.2 Hospital Pharmacies- Market Size and Forecast (2016-2026)

6.3 Retail Pharmacies- Market Size and Forecast (2016-2026)

6.4 Online Pharmacies- Market Size and Forecast (2016-2026)

7. Global Gastroesophageal Reflux Disease Therapeutics Market: Regional Analysis

7.1 Competitive Scenario of Global Gastroesophageal Reflux Disease Therapeutics Market: By Region

8. North America Gastroesophageal Reflux Disease Therapeutics Market: An Analysis (2016-2026)

9. Europe Gastroesophageal Reflux Disease Therapeutics Market: An Analysis (2016-2026)

10. Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market: An Analysis (2016-2026)

11. Global Gastroesophageal Reflux Disease Therapeutics Market Dynamics

11.1 Global Gastroesophageal Reflux Disease Therapeutics Market Drivers

11.2 Global Gastroesophageal Reflux Disease Therapeutics Market Restraints

11.3 Global Gastroesophageal Reflux Disease Therapeutics Market Trends

12. Market Attractiveness

13. Competitive Landscape

13.1 Market Share Analysis

13.2 Gastroesophageal Reflux Disease Therapeutics Pipeline

14. Company Profiles

For more information about this report visit https://www.researchandmarkets.com/r/94wddu

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900